Heartflow (HTFL) Stock Price, News & Analysis

Company Overview

HeartFlow, Inc. (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact. The output is intended to support diagnostic decision-making—helping to triage patients, reduce unnecessary invasive coronary angiography, and guide treatment planning such as the need for percutaneous coronary intervention or medical management. The company positions its technology as a tool for cardiology, radiology and emergency-department pathways where non-invasive assessment of coronary physiology can improve patient care.

The company works with hospitals, imaging centers and health systems and has expanded its commercial presence beyond the U.S. into multiple international markets. HeartFlow pursues collaborations with clinical research groups and payers to support adoption and reimbursement, and it emphasizes evidence from clinical studies demonstrating the clinical utility of physiology-based CT analysis. The business model centers on a software-as-a-service delivery of advanced image analysis and clinical reporting to support precision diagnostics in cardiovascular care.

Key Stats

• Today's Range: $30.00 to $33.67
• 50-Day Range: $24.83 to $33.24
• 52-Week Range: $20.13 to $41.22
• Volume: 1.89 million shs
• Average Volume: 1.16 million shs
• Market Capitalization: $2.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.00
• Consensus Rating: Moderate Buy

Heartflow Stock Analysis - MarketRank™

Heartflow scored higher than 43% of companies evaluated by MarketBeat, and ranked 555th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Heartflow has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Heartflow has a consensus price target of $37.00, representing about 11.3% upside from its current price of $33.24.

Amount of Analyst Coverage

Heartflow has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Heartflow are expected to grow in the coming year, from ($0.82) to ($0.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Heartflow is -10.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Heartflow is -10.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Heartflow has a P/B Ratio of 9.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.57% of the float of Heartflow has been sold short.

Short Interest Ratio / Days to Cover

Heartflow has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Heartflow has recently increased by 4.53%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Heartflow does not currently pay a dividend.

Dividend Growth

Heartflow does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.44

News Sentiment

Heartflow has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Heartflow this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 1 people have added Heartflow to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Heartflow insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,552,076.00 in company stock.

Percentage Held by Insiders

7.70% of the stock of Heartflow is held by insiders.

Percentage Held by Institutions

Heartflow has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:HTFL
• Previous Symbol: NASDAQ:HTFL
• CIK: 1464521
• Web: www.heartflow.com
• Phone: 650 241 1221
• Fax: N/A
• Employees: 699
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Heartflow: $37.00
• High Price Target: $40.00
• Low Price Target: $35.00
• Potential Upside/Downside: +11.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$116.79 million
• Net Margins: -58.42%
• Pretax Margin: -58.45%
• Return on Equity: N/A
• Return on Assets: -20.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.57
• Quick Ratio: 5.57

Sales & Book Value

• Annual Sales: $176.03 million
• Price / Sales: 16.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.53 per share
• Price / Book: 9.42

Miscellaneous

• Outstanding Shares: 86,240,000
• Free Float: 79,600,000
• Market Cap: $2.87 billion
• Optionable: N/A
• Beta: N/A